[Webinar] Use of Real World Evidence in Clinical Development to Enhance Regulatory Submission

More pharmaceutical companies are working to understand how real world evidence (RWE) can strengthen their submission packages and identifying opportunities to do this across their portfolios. Join Nathalie Horowicz-Mehler, Senior Principal and Practice Lead of the Real World Evidence (RWE) team at IQVIA as she shares how RWE can be utilized to enhance regulatory submissions through three key takeaways:

• Improved understanding of global receptivity to RWE in Regulatory Submission including FDA, EMA, and Japan
• Understand how to identify an opportunity for RWE to inform submission package for your product or portfolio
• Use cases of real-world evidence in Regulatory Submission for effectiveness, especially for label expansions

Event is open to: HBA Members and Nonmembers. Register here by December 1st.